- Home
- FBGL vs MYNZ Comparison
FBGL vs MYNZ Comparison
Compare FBGL & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBGL
- MYNZ
- Stock Information
- Founded
- FBGL 1996
- MYNZ 2021
- Country
- FBGL Singapore
- MYNZ Germany
- Employees
- FBGL N/A
- MYNZ N/A
- Industry
- FBGL Miscellaneous manufacturing industries
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- FBGL Consumer Discretionary
- MYNZ Health Care
- Exchange
- FBGL Nasdaq
- MYNZ Nasdaq
- Market Cap
- FBGL 8.5M
- MYNZ 7.9M
- IPO Year
- FBGL 2025
- MYNZ 2021
- Fundamental
- Price
- FBGL $0.62
- MYNZ $1.64
- Analyst Decision
- FBGL
- MYNZ Buy
- Analyst Count
- FBGL 0
- MYNZ 2
- Target Price
- FBGL N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- FBGL 494.6K
- MYNZ 146.6K
- Earning Date
- FBGL 01-01-0001
- MYNZ 10-21-2025
- Dividend Yield
- FBGL N/A
- MYNZ N/A
- EPS Growth
- FBGL N/A
- MYNZ N/A
- EPS
- FBGL N/A
- MYNZ N/A
- Revenue
- FBGL $10,146,582.00
- MYNZ $893,991.00
- Revenue This Year
- FBGL N/A
- MYNZ $26.06
- Revenue Next Year
- FBGL N/A
- MYNZ $4.97
- P/E Ratio
- FBGL N/A
- MYNZ N/A
- Revenue Growth
- FBGL N/A
- MYNZ N/A
- 52 Week Low
- FBGL $0.44
- MYNZ $1.30
- 52 Week High
- FBGL $5.45
- MYNZ $16.32
- Technical
- Relative Strength Index (RSI)
- FBGL N/A
- MYNZ 47.16
- Support Level
- FBGL N/A
- MYNZ $1.70
- Resistance Level
- FBGL N/A
- MYNZ $1.85
- Average True Range (ATR)
- FBGL 0.00
- MYNZ 0.12
- MACD
- FBGL 0.00
- MYNZ 0.00
- Stochastic Oscillator
- FBGL 0.00
- MYNZ 46.81
About FBGL FBS Global Limited Ordinary Shares
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.